[Rheumatoid arthritis. Conservative therapeutic possibilities today and in the future].
During the past few years the treatment of rheumatoid arthritis, the most frequent of the rheumatic inflammatory systemic diseases has improved a great deal. The treatment strategy is based on the one hand on the so-called prognostic factors and on the other hand on the extent of the inflammatory activities, especially during the first phase. Numerous controlled studies and meta-analyses have enabled optimal application of the basic disease-modifying drugs, with regard to efficacy and side effects. During the first stage of these disease, the immunobiological substances against pro-inflammatory cells are employed. Improved knowledge of physiotherapeutic treatment, correct diet and careful observation of the patient's progress with the aid of questionnaires enable optimal care with regard to life quality.
Aeschlimann
A G
AG
Rheuma- und Rehaklinik Zürich.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000209:etiology / Q000235:genetics / Q000628:therapy*; D016572:Cyclosporine / Q000627:therapeutic use; D005544:Forecasting; D006046:Gold / Q000627:therapeutic use; D006801:Humans; D010396:Penicillamine / Q000627:therapeutic use; D012460:Sulfasalazine / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000894:Anti-Inflammatory Agents, Non-Steroidal; D018501:Antirheumatic Agents; D012460:Sulfasalazine; D006046:Gold; D016572:Cyclosporine; D010396:Penicillamine
Rheumatoide Arthritis. Konservative Therapiemöglichkeiten heute und in der Zukunft.